Risk for Bleeding-Related Hospitalizations During Use of Amiodarone With Apixaban or Rivaroxaban in Patients With Atrial Fibrillation

医学 胺碘酮 拜瑞妥 阿哌沙班 心房颤动 内科学 华法林 心脏病学 冲程(发动机) 达比加群 大出血 麻醉 机械工程 工程类
作者
Wayne A. Ray,Cecilia P. Chung,C. Michael Stein,Walter Smalley,Eli E. Zimmerman,William D. Dupont,Adriana M. Hung,James R. Daugherty,Alyson L. Dickson,Katherine T. Murray
出处
期刊:Annals of Internal Medicine [American College of Physicians]
卷期号:176 (6): 769-778 被引量:13
标识
DOI:10.7326/m22-3238
摘要

Amiodarone, the most effective antiarrhythmic drug in atrial fibrillation, inhibits apixaban and rivaroxaban elimination, thus possibly increasing anticoagulant-related risk for bleeding. For patients receiving apixaban or rivaroxaban, to compare risk for bleeding-related hospitalizations during treatment with amiodarone versus flecainide or sotalol, antiarrhythmic drugs that do not inhibit these anticoagulants' elimination. Retrospective cohort study. U.S. Medicare beneficiaries aged 65 years or older. Patients with atrial fibrillation began anticoagulant use between 1 January 2012 and 30 November 2018 and subsequently initiated treatment with study antiarrhythmic drugs. Time to event for bleeding-related hospitalizations (primary outcome) and ischemic stroke, systemic embolism, and death with or without recent (past 30 days) evidence of bleeding (secondary outcomes), adjusted with propensity score overlap weighting. There were 91 590 patients (mean age, 76.3 years; 52.5% female) initiating use of study anticoagulants and antiarrhythmic drugs, 54 977 with amiodarone and 36 613 with flecainide or sotalol. Risk for bleeding-related hospitalizations increased with amiodarone use (rate difference [RD], 17.5 events [95% CI, 12.0 to 23.0 events] per 1000 person-years; hazard ratio [HR], 1.44 [CI, 1.27 to 1.63]). Incidence of ischemic stroke or systemic embolism did not increase (RD, -2.1 events [CI, -4.7 to 0.4 events] per 1000 person-years; HR, 0.80 [CI, 0.62 to 1.03]). The risk for death with recent evidence of bleeding (RD, 9.1 events [CI, 5.8 to 12.3 events] per 1000 person-years; HR, 1.66 [CI, 1.35 to 2.03]) was greater than that for other deaths (RD, 5.6 events [CI, 0.5 to 10.6 events] per 1000 person-years; HR, 1.15 [CI, 1.00 to 1.31]) (HR comparison: P = 0.003). The increased incidence of bleeding-related hospitalizations for rivaroxaban (RD, 28.0 events [CI, 18.4 to 37.6 events] per 1000 person-years) was greater than that for apixaban (RD, 9.1 events [CI, 2.8 to 15.3 events] per 1000 person-years) (P = 0.001). Possible residual confounding. In this retrospective cohort study, patients aged 65 years or older with atrial fibrillation treated with amiodarone during apixaban or rivaroxaban use had greater risk for bleeding-related hospitalizations than those treated with flecainide or sotalol. National Heart, Lung, and Blood Institute.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
1秒前
1秒前
1秒前
CHAO完成签到,获得积分10
1秒前
田様应助wdlc采纳,获得10
2秒前
angewbaby发布了新的文献求助10
2秒前
fcyyc发布了新的文献求助30
2秒前
goodsheep完成签到 ,获得积分10
2秒前
Ray完成签到,获得积分10
2秒前
3秒前
4秒前
4秒前
aaa发布了新的文献求助10
4秒前
Xixicccccccc完成签到 ,获得积分10
5秒前
Young_89发布了新的文献求助10
5秒前
SciGPT应助rui采纳,获得10
5秒前
大胆又夏发布了新的文献求助10
5秒前
6秒前
Hayley发布了新的文献求助10
6秒前
开心擎完成签到,获得积分20
6秒前
6秒前
fffxuy发布了新的文献求助10
7秒前
Ym完成签到,获得积分10
7秒前
跳跃寒风发布了新的文献求助10
7秒前
娟儿完成签到,获得积分10
7秒前
DijiaXu应助cxb采纳,获得10
7秒前
8秒前
8秒前
222222关注了科研通微信公众号
9秒前
yqwang发布了新的文献求助10
9秒前
9秒前
10秒前
我是老大应助runner采纳,获得10
11秒前
11秒前
邓紫棋完成签到,获得积分10
11秒前
12秒前
12秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975165
求助须知:如何正确求助?哪些是违规求助? 3519595
关于积分的说明 11198781
捐赠科研通 3255912
什么是DOI,文献DOI怎么找? 1798001
邀请新用户注册赠送积分活动 877343
科研通“疑难数据库(出版商)”最低求助积分说明 806298